Try our Advanced Search for more refined results

In Re: Testosterone Replacement Therapy Products Liability Litigation

Track this case

Case overview

Case Number:

1:14-cv-01748

Court:

Illinois Northern

Nature of Suit:

367(Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability)

Judge:

Honorable Matthew F. Kennelly

Firms

Companies

Government Agencies

Sectors & Industries:

  1. November 03, 2017

    AbbVie Says Evidence Doesn't Back $140M AndroGel Verdict

    AbbVie Inc. asked an Illinois federal judge to enter judgment in its favor in the second bellwether trial over claims the company failed to warn consumers about risks accompanying its drug AndroGel, arguing Thursday the jury's verdict and $140 million punitive damages award aren't supported by the evidence.

  2. October 26, 2017

    Defeated AndroGel User Must Pay Own Bills, AbbVie Says

    An Illinois federal jury was right to deny an Androgel user money to cover his medical bills after it found the AbbVie Inc. drug didn't cause his heart attack, even though the same jury found the company was on the hook for $150 million in punitive damages tied to false advertising, AbbVie told the court Wednesday.

  3. October 03, 2017

    AbbVie's Marketing Of AndroGel 'Insidious,' Jury Told

    Attorneys for a man who had a heart attack while using AbbVie Inc.'s testosterone replacement therapy drug AndroGel told an Illinois federal jury Tuesday the company's efforts to expand the drug's market without studying its risks were part of an "insidious" plan to up its profits.

  4. September 18, 2017

    AbbVie Failed To Study Risks Of AndroGel, Jury Told

    AbbVie dodged its responsibility to test AndroGel to see whether users faced an increased risk of heart attack, attorneys for a man suing the company told an Illinois federal jury Monday at the start of the second bellwether trial in the multidistrict litigation over testosterone gel products.

  5. September 06, 2017

    CORRECTION: AbbVie Can't Argue AndroGel Suit Too Late

    An Illinois federal judge refused to reconsider an earlier ruling on whether an AndroGel user’s claims against AbbVie are barred by state statute of repose and statute of limitations Wednesday, shutting the door on some of the drugmaker’s defenses ahead of the next bellwether in the multidistrict litigation. Correction: An earlier version of this story misstated the ruling made by Judge Kennelly. The error has been corrected.

  6. August 22, 2017

    AbbVie, Patient Both Say Jury On Their Side In $150M Award

    AbbVie Inc. and an AndroGel user who claimed the product caused his heart attack attempted to salvage their unusual jury verdict Monday, with both sides telling an Illinois federal judge the panel's $150 million award sent a clear message in their favor.

  7. August 03, 2017

    Hurdles Ahead For AbbVie After $150M AndroGel Verdict

    An Illinois federal jury may have cleared AbbVie of causing an AndroGel user's heart attack, but its award of $150 million in punitive damages against the drugmaker for misleading advertising saddles AbbVie with clear challenges in future trials in multidistrict litigation, attorneys say.

  8. July 24, 2017

    AbbVie Must Pay $150M For False AndroGel Ads, Jury Says

    An Illinois federal jury on Monday found that AbbVie Inc. isn't liable for an AndroGel user's heart attack but ordered the company to pay $150 million in punitive damages for funding ads that misrepresented what the testosterone replacement therapy drug could treat.

  9. July 21, 2017

    Jury Begins Deliberations In Suit Over AbbVie's AndroGel

    A man who claims he had a heart attack after using AbbVie Inc.'s testosterone replacement therapy drug AndroGel made his final plea to the Illinois federal jury hearing his case Friday, saying every decision the company made about the product had "consequences for real people."

  10. July 19, 2017

    FDA Heard All Stories Of AndroGel Heart Attacks, Jury Told

    An AbbVie Inc. executive who monitored the safety of the company's products told an Illinois federal jury Wednesday that the U.S. Food and Drug Administration had all the company's information on heart attacks suffered by people on AndroGel but repeatedly declined to ask for a study on the risk.